EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer

Johan Maertens, Tom Lodewyck, J Peter Donnelly, Sylvain Chantepie, Christine Robin, Nicole Blijlevens, Pascal Turlure, Dominik Selleslag, Frédéric Baron, Mickael Aoun, Werner J Heinz, Hartmut Bertz und 20 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac623 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Johan Maertens und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Mycoses, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme Corp,.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown.

Methods

Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically. The primary end point of this noninferiority study was overall survival (OS) 42 days after randomization.

Results

Of 556 patients recruited, 549 were eligible: 275 in arm A and 274 in arm B. Eighty percent of the patients had AML or MDS requiring high-dose chemotherapy, and 93% of them were in the first induction phase. At day 42, the OS was not inferior in arm B (96.7%; 95% confidence interval [CI], 93.8%–98.3%) when compared with arm A (93.1%; 95% CI, 89.3%–95.5%). The rates of IFDs at day 84 were not significantly different, 7.7% (95% CI, 4.5%–10.8%) in arm B vs 6.6% (95% CI, 3.6%–9.5%) in arm A. The rate of patients who received caspofungin was significantly lower in arm B (27%) than in arm A (63%; P < .001).

Conclusions

The preemptive antifungal strategy was safe for high-risk neutropenic patients given fluconazole as prophylaxis, halving the number of patients receiving antifungals without excess mortality or IFDs. Clinical Trials Registration. NCT01288378; EudraCT 2010-020814-27.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MycosesHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesHumansAntifungal AgentsFluconazoleCaspofungin

Stichwörter der Autor:innen

antifungalempiricgalactomannanneutropeniapreemptive

Substanzen

Antifungal AgentsFluconazoleCaspofungin

Autor:innen und Institutionen

  • Department of Hematology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Hematology, Algemeen Ziekenhuis St Jan, Brugge, Belgium.
  • Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Hematology, Caen University Hospital, Caen, France.
  • Department of Hematology, Centre Hospitalier Universitaire Henri Mondor, Créteil, France.
  • Department of Hematology, Centre Hospitalier Universitaire Limoges, Limoges, France.

ORCID-Profile: Paul Verweij

Förderung

  • Merck Sharp & Dohme Corp,

Zitieren

APA

Maertens, J., Lodewyck, T., Donnelly, J. P., Chantepie, S., Robin, C., Blijlevens, N., Turlure, P., Selleslag, D., Baron, F., Aoun, M., Heinz, W. J., Bertz, H., Ráčil, Z., Vandercam, B., Drgona, L., Coiteux, V., Llorente, C. C., Schaefer-Prokop, C., Paesmans, M., …, & Infectious Diseases Group and the Acute Leukemia Group of the European Organization for Research and Treatment of Cancer (2023). Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac623

Vancouver

Maertens J, Lodewyck T, Donnelly JP, Chantepie S, Robin C, Blijlevens N, et al. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac623

BibTeX
@article{Maertens2023,
  author = {Maertens, Johan and Lodewyck, Tom and Donnelly, J Peter and Chantepie, Sylvain and Robin, Christine and Blijlevens, Nicole and Turlure, Pascal and Selleslag, Dominik and Baron, Frédéric and Aoun, Mickael and Heinz, Werner J and Bertz, Hartmut and Ráčil, Zdeněk and Vandercam, Bernard and Drgona, Lubos and Coiteux, Valerie and Llorente, Cristina Castilla and Schaefer-Prokop, Cornelia and Paesmans, Marianne and Ameye, Lieveke and Meert, Liv and Cheung, Kin Jip and Hepler, Deborah A and Loeffler, Jürgen and Barnes, Rosemary and Marchetti, Oscar and Verweij, Paul and Lamoth, Frederic and Bochud, Pierre-Yves and Schwarzinger, Michael and Cordonnier, Catherine and Infectious Diseases Group and the Acute Leukemia Group of the European Organization for Research and Treatment of Cancer, Infectious Diseases Group and the Acute Leukemia Group of the European Organization for Research and Treatment of Cancer},
  title = {Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac623}
}
Kostenlos starten →